Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).

被引：1
|
作者：
Ferrarotto, Renata
Mata, Javier
Mott, Frank
Bhosale, Priya
Rubin, M. Laura
Altan, Mehmet
Dervin, Shannon
Yun, Cindy
Yao, James C.
Halperin, Daniel M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Genentech Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e21006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21006
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study
    Wang, Lu
    Zhang, Ti
    Lin, Zhenhai
    Zhou, Jiamin
    Wan, Juefeng
    Pan, Qi
    Zhao, Yiming
    Zhu, Weiping
    Mao, Anrong
    Zhang, Ning
    Wang, Longrong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Preliminary results of sintilimab (Sin) plus bevacizumab (Bev) in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
    Liu, X.
    Xia, B.
    Zhang, W.
    Sun, L.
    Feng, C.
    Huang, Y.
    Gao, Y.
    Jiang, J.
    Li, G.
    Gao, Q.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S783 - S783
  • [23] Treatment of advanced or metastatic hepatocellular cancer (HCC): Final clinical results of a single-arm phase II study of bevacizumab and everolimus
    Treiber, Gerhard
    Wex, Thomas
    Schneider, Guenther
    Roecken, Cristoph
    Dufour, Jean-Francois
    Geisel, Juergen
    Hardikar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] Final results of a single-arm phase II study of bevacizumab and temozolomide following radiochemotherapy in newly dignosed adult glioblastoma patients
    Nicholas, Martin Kelly
    Lukas, Rimas Vincas
    Amidei, Christine
    Vick, Nicholas
    Paleologos, Nina
    Malkin, Mark Gordon
    Krouwer, Hendrikus
    Junck, Larry
    Arzbaecher, Jean
    Lai, Albert
    Merrell, Ryan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
    Feng, Zizhen
    Curti, Brendan D.
    Quinn, David I.
    Strother, John M.
    Chen, Zunqiu
    Agnor, Rebecca
    Beer, Tomasz M.
    Ryan, Christopher W.
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 415 - 422
  • [26] Updated results from POD1UM-201: A phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC)
    Grignani, G.
    Rutkowski, P.
    Lebbe, C.
    Guida, M.
    Marqueste, C. Gaudy
    De Braud, F. G. M.
    Spagnolo, F.
    Burgess, M.
    Montaudie, H.
    Depenni, R.
    Spada, F.
    Pulini, J.
    Cornfeld, M.
    Tian, C.
    Bhatia, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S686 - S686
  • [27] EFFICACY AND SAFETY OF AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: INTERIM RESULTS FROM THE OPEN-LABEL, SINGLE-ARM, PHASE 2 PATHFINDER STUDY
    Vannucchi, A. M.
    DeAngelo, D. J.
    Reiter, A.
    Radia, D.
    Deininger, M. W.
    George, T. I.
    Panse, J.
    Jentzsch, M.
    Alvarez-Twose, I.
    Mital, A.
    Hermine, O.
    Dybedal, I.
    Hexner, E. O.
    Hicks, L. K.
    Span, L.
    Mesa, R.
    Bose, P.
    Pettit, K. M.
    Heaney, M. L.
    Oh, S.
    Sen, J.
    Lin, H-M.
    Mar, B. G.
    Gotlib, J.
    HAEMATOLOGICA, 2021, 106 (10) : 2 - 2
  • [28] Efficacy of sintilimab plus bevacizumab in recurrent/persistent ovarian clear cell carcinoma (INOVA): A multicenter, single-arm, phase II trial
    Gao, Qinglei
    Liu, Xingyu
    Xia, Bairong
    Zhang, Wei
    Sun, Li
    Feng, Cui
    Huang, Yi
    Gao, Yunong
    Jiang, Jie
    Li, Guiling
    Zhang, Yu
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S37 - S37
  • [29] Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
    McGregor, Bradley A.
    McKay, Rana R.
    Braun, David A.
    Werner, Lillian
    Gray, Kathryn P.
    Flaifel, Abdallah
    Signoretti, Sabina
    Hirsch, Michelle S.
    Steinharter, John A.
    Bakouny, Ziad
    Flippot, Ronan
    Wei, Xiao X.
    Choudhury, Atish
    Kilbridge, Kerry
    Freeman, Gordon J.
    Van Allen, Eliezer
    Harshman, Lauren C.
    McDermott, David F.
    Vaishampayan, Ulka
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (01) : 63 - +
  • [30] Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study
    Wang, Kang
    Liu, Zong-Han
    Yu, Hong-Ming
    Cheng, Yu-Qiang
    Xiang, Yan-Jun
    Zhong, Jing-Ya
    Ni, Qian-Zhi
    Zhou, Li-Ping
    Liang, Chao
    Zhou, Hong-Kun
    Pan, Wei-Wei
    Guo, Wei-Xing
    Shi, Jie
    Cheng, Shu-Qun
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
12345